started · updated
Cocrystal Pharma and Quantum BioPharma report third quarter financial results
Cocrystal Pharma reported a wider third quarter loss of $3.444 million, or $0.20 per share, compared to a loss of $2.049 million in the previous year. The increase in loss was driven by higher operating expenses, which rose to $3.594 million. Research and development costs reached $1.978 million, primarily due to the Phase 1b norovirus challenge study for its candidate CDI-988. Preliminary efficacy results for this study are expected by the end of 2026. The company reported $4.873 million in unrestricted cash as of September 30.
Quantum BioPharma reported third quarter results for the period ending September 30, 2026, noting $12.22 million in combined cash and digital assets. The company reported a 24% year-over-year decline in operating expenses and a 26% narrowing of its nine-month net loss to $17.32 million.
Following FDA clearance of its Investigational New Drug application, Quantum BioPharma entered a study start-up agreement with Thermo Fisher Scientific to implement a Phase 2 clinical trial for Lucid-MS, a candidate for progressive multiple sclerosis. Management stated that current holdings are sufficient to support operations for the next 12 months.
Entities
Cocrystal Pharma, Inc. · OPKO Health, Inc. · Quantum BioPharma · Thermo Fisher Scientific · U.S. Food and Drug Administration